Jonathan Seaton - Illumina President
| ILMN Stock | USD 116.69 1.60 1.35% |
President
Mr. Jonathan Seaton was appointed as Senior Vice President Corporationrationrate Business Development of the Company effective January 3, 2017. Further strengthening its executive team as the company continues reinforcing the foundation for longterm growth. Jonathan will be responsible for global business development activities, including strategic commercial deals, mergers and acquisitions, licensing and partnerships. He joins Illumina from Becton, Dickinson and Company where he was Vice President and Head of Strategy and Business Development for the Life Sciences segment. He previously held leadership roles at F. HoffmanLa Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks. Jonathan studied medicine at the University of Manchester, received a BSc degree in Molecular Biology and Biochemistry from the University of Durham, and an MBA from the Sad Business School at the University of Oxford. since 2017.
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 5200 Illumina Way, San Diego, CA, United States, 92122 |
| Phone | 858 202 4500 |
| Web | https://www.illumina.com |
Illumina Management Efficiency
As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.0086. At this time, Illumina's Debt To Assets are very stable compared to the past year. As of the 19th of April 2024, Fixed Asset Turnover is likely to grow to 3.35, while Non Currrent Assets Other are likely to drop about 123.4 M. Illumina's management efficiency ratios could be used to measure how well Illumina manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Gloria McCarthy | AN2 Therapeutics | 63 | |
| Wayne DeVeydt | AN2 Therapeutics | 45 | |
| Greg Poulakos | AN2 Therapeutics | N/A | |
| Morgan Kendrick | AN2 Therapeutics | N/A | |
| John Gallina | AN2 Therapeutics | 56 | |
| Douglas Simpson | AN2 Therapeutics | N/A | |
| Jose Tomas | AN2 Therapeutics | 48 | |
| Michael Malouf | AN2 Therapeutics | N/A | |
| Brian Griffin | AN2 Therapeutics | 57 | |
| Peter Haytaian | AN2 Therapeutics | 46 | |
| Samuel Nussbaum | AN2 Therapeutics | 65 | |
| Craig Samitt | AN2 Therapeutics | 51 | |
| Martin Silverstein | AN2 Therapeutics | 47 | |
| Bonnie Jacobs | AN2 Therapeutics | N/A | |
| Thomas Zielinski | AN2 Therapeutics | 65 | |
| Jacquelyn Wolf | AN2 Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0053 |
Illumina Leadership Team
Elected by the shareholders, the Illumina's board of directors comprises two types of representatives: Illumina inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Illumina. The board's role is to monitor Illumina's management team and ensure that shareholders' interests are well served. Illumina's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Illumina's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paula Dowdy, Senior Vice President and General Manager | ||
| Richard Klausner, Chief Medical Officer & Interim General Manager, Oncology | ||
| Karen McGinnis, Vice President Chief Accounting Officer, Principal Accounting Officer | ||
| David Walt, Founder, Director and Member of Nominating and Corporate Governance Committee | ||
| Philip Schiller, Director | ||
| Steven Hoffman, Segment Sequencing | ||
| Roy Whitfield, Independent Director | ||
| Jeffrey Huber, Director | ||
| Pat Leckman, Interim Officer | ||
| Aimee Hoyt, Senior Vice President and Chief People Officer | ||
| Garret Hampton, Executive Vice President - Clinical Genomics | ||
| John Thompson, Director | ||
| Frances Arnold, Director | ||
| Christian Henry, Chief Commercial Officer and Executive VP | ||
| Caroline Dorsa, Director | ||
| Daniel Bradbury, Independent Director | ||
| Sharon Vidal, Global Responsibility | ||
| Nicholas Naclerio, Senior Vice President Corporate Development & General Manager - Enterprise Informatics | ||
| Susan Siegel, Director | ||
| Susan Tousi, Chief Officer | ||
| Omead Ostadan, Executive Vice President - Operations, Products and Strategy | ||
| Phillip Febbo, Chief Medical Officer | ||
| Steven Barnard, Chief Officer | ||
| Stephanie Campos, President | ||
| Gretchen Weightman, Middle Pacific | ||
| William Rastetter, Independent Chairman of the Board | ||
| Jacquie Ross, Vice President Investor Relations | ||
| Robert Epstein, Independent Director | ||
| Paul Bianchi, Senior Vice President - Human Resources | ||
| Jonathan Seaton, Senior Vice President - Corporate & Business Development | ||
| Francis deSouza, Pres and Director | ||
| Jacob Thaysen, CEO Director | ||
| Karin Eastham, Independent Director | ||
| Charles Dadswell, Senior Vice President General Counsel, Secretary | ||
| Ankur Dhingra, Chief Officer | ||
| Nicole Berry, Head RegionAmericas | ||
| Rebecca Chambers, Senior Director - Investor Relations | ||
| Mena Farag, Senior Specialist | ||
| Sanjay Chikarmane, Senior Vice President General Manager | ||
| Sam Samad, CFO, Senior Vice President | ||
| Scott Ericksen, VP Officer | ||
| Kevin Pegels, Chief Operations | ||
| Charles Esq, Senior Counsel | ||
| Joydeep MBA, Executive Officer | ||
| Bas Verhoef, Interim RegionEurope | ||
| Sallilyn Schwartz, Vice Relations | ||
| Mark Oene, Senior Vice President Chief Commercial Officer | ||
| Arthur Bowman, Independent Director | ||
| Gary Guthart, Director | ||
| Kathryne Reeves, Chief Officer | ||
| Jay Flatley, Chairman and CEO | ||
| Mostafa Ronaghi, CTO, Senior Vice President | ||
| Alexander MD, CTO Devel | ||
| Carissa Rollins, Chief Officer | ||
| Tristan Orpin, Senior Vice President & General Manager, Reproductive and Genetic Health | ||
| Jenny Zheng, Head China | ||
| Marc Stapley, CFO, Chief Admin. Officer and Executive VP |
Illumina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Illumina a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.0053 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 19.73 B | ||||
| Shares Outstanding | 159.26 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 94.47 % | ||||
| Number Of Shares Shorted | 5.28 M | ||||
| Price To Earning | 49.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Illumina Stock analysis
When running Illumina's price analysis, check to measure Illumina's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Illumina is operating at the current time. Most of Illumina's value examination focuses on studying past and present price action to predict the probability of Illumina's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Illumina's price. Additionally, you may evaluate how the addition of Illumina to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Illumina's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (7.35) | Revenue Per Share 28.506 | Quarterly Revenue Growth 0.036 | Return On Assets (0.01) |
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.